/sixth-igwg-meeting-resumed---front-of-meeting-room.tmb-1200v.jpg?sfvrsn=6c365fb6_4 "sixth-igwg-meeting-resumed—front-of-meeting-room.tmb-1200v.jpg")
The global effort to build a legally binding shield against future pandemics has hit a familiar, complex snag: the tension between scientific urgency and geopolitical equity. Member states of the World Health Organization (WHO) have agreed to extend negotiations on the Pathogen Access and Benefit Sharing (PABS) annex, a critical component of the broader WHO Pandemic Agreement that remains the most contentious piece of the puzzle.
The decision comes after the conclusion of the sixth meeting of the Intergovernmental Working Group (IGWG) in Geneva. While officials reported “real progress,” the technical and legal intricacies of how countries share deadly viruses—and who gets the vaccines derived from them—have proven too dense to resolve within the original timeframe. The outcome of these discussions will be presented to the World Health Assembly (WHA), where member states will consider extending the mandate to finalize the framework by May 2027, or potentially sooner through a special session in 2026.
For those of us in the medical community, this delay is more than a bureaucratic hurdle; This proves a reflection of a systemic failure that plagued the early days of the COVID-19 pandemic. As a physician, I have seen how the gap between the discovery of a pathogen and the delivery of a vaccine can be measured in millions of lives. The PABS system is designed to bridge that gap, ensuring that the “access” (sharing the virus) is inextricably linked to the “benefit” (sharing the cure).
The High Stakes of Pathogen Sharing
At its core, the PABS system addresses a fundamental trade-off. For scientists to develop diagnostics and vaccines, they need rapid, unfettered access to the genetic sequences of emerging pathogens. This typically happens when a country identifies a new outbreak and shares the sample with the global community via the WHO.
However, history has shown that this sharing is often a one-way street. During previous health crises, low- and middle-income countries provided the viral samples that allowed pharmaceutical companies in wealthy nations to develop life-saving treatments. Yet, when those treatments hit the market, the countries that provided the original data were often the last to receive them, priced out or pushed to the back of the queue.
“The PABS annex is the last piece of the puzzle,” WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated, emphasizing that the next pandemic is a matter of “when, not if.” The goal is to create a reciprocal system: if a country shares a pathogen with pandemic potential, they are guaranteed a fair share of the resulting vaccines, therapeutics, and diagnostics on an equitable footing.
The Deadlock: Access vs. Equity
The negotiations have stalled primarily over the definition of “equitable sharing.” High-income nations and the pharmaceutical industry often emphasize the need for intellectual property protections and streamlined processes to ensure innovation isn’t stifled. Conversely, many developing nations argue that without guaranteed, affordable access to the end products, they have little incentive to risk the economic and political fallout of reporting and sharing a new pathogen.
The legal complexity mentioned by Ambassador Tovar da Silva Nunes of Brazil refers to how these benefits are triggered. Negotiators are debating whether the “benefit” should be a fixed percentage of production, a tiered pricing model, or a direct transfer of technology to allow countries to manufacture their own vaccines.
| Feature | Pathogen Access (The “Give”) | Benefit Sharing (The “Get”) |
|---|---|---|
| Primary Action | Rapid sharing of biological samples and genetic sequences. | Guaranteed access to vaccines, tests, and medicines. |
| Key Driver | Global surveillance and early warning systems. | Health equity and affordable public health tools. |
| Main Obstacle | National security concerns and biological sovereignty. | Intellectual property rights and profit margins. |
| Desired Outcome | Immediate identification of pandemic threats. | Universal distribution based on need, not wealth. |
A Timeline for Global Readiness
The path to a finalized agreement has been a marathon of diplomatic maneuvering. While the broader Pandemic Agreement was adopted in principle to strengthen prevention and response, the PABS annex serves as the operational engine that makes the agreement enforceable.
- May 2025: The World Health Assembly adopted the overarching Pandemic Agreement, establishing the IGWG to hammer out the technical details.
- Current Status: The sixth IGWG meeting ended with a consensus that the PABS framework requires more precision and dedication before ratification.
- July 2026: The IGWG is scheduled to hold its seventh meeting (July 6–17) to continue refining the annex.
- May 2027: The current target for submitting the final outcome to the World Health Assembly, unless a special session is called in 2026.
Why This Delay Matters
From a public health perspective, a rushed agreement that is not ratified by enough member states is as useless as no agreement at all. The “precision” Ambassador Nunes referenced is necessary to ensure the document is legally binding and politically palatable across diverse economic landscapes. If the PABS system is too weak, countries may hesitate to report new outbreaks. If it is too restrictive, it could slow the speed of vaccine development.
The stakeholders involved—ranging from the WHO and national health ministries to biotech firms and NGOs—are essentially trying to rewrite the social contract of global health. The goal is to move away from a charity-based model (where wealthy nations “donate” leftover doses) toward a rights-based model (where access is a pre-negotiated guarantee).
Disclaimer: This article is provided for informational purposes only and does not constitute legal or medical advice. For official guidance on pandemic preparedness, please consult the World Health Organization.
The next critical checkpoint will be the upcoming Seventy-ninth World Health Assembly, where member states will formally vote on the extension of the IGWG’s mandate. This vote will determine whether the world continues to move toward a unified response framework or remains fragmented in the face of the next inevitable biological threat.
Do you believe a guaranteed sharing of vaccines is a fair trade for pathogen data? Share your thoughts in the comments or share this story to join the conversation.
Related reading
